



OCT 20 1999

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. John Plumadore
AngioLaz, Incorporated
P.O. Box 556
Industrial Park

Bellows Falls, VT 05101

Re: K992447

VES 0501, 50 Watt Metal Halide Illuminator

Dated: July 20, 1999 Received: July 22, 1999 Regulatory Class: I

21 CFR 876.1500/Procode: 78 FCW, FCR, FFS, GCT

Dear Mr. Plumadore:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May, 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the <u>Code of Federal Regulations</u>, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

CAPT Daniel G. Schultz, M.D.

Acting Director, Division of Reproductive,

Abdominal, Ear, Nose and Throat,

and Radiological Devices
Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

••	
Page_/_	<u>−δι</u>

· -		••	
	•	Page_/o(_/_	\ \ \ \
510(k) Number (if known):/	K 992447		•
Device Name: VES 05	501	-	
Indications For Use:			
<ul> <li>There is a requirement</li> <li>There is a requirement</li> <li>There is a requirement</li> </ul>	nt for illuminating r nt for fiber-optic ill nt to use video as a	icated use in the following situations: medical headlamps. umination for endoscopy applications. visual aid or a method of recording or bothe above at the same time.	th.
	·		
(PLEASE DO NOT WRITE B NEEDED)	ELOW THIS LINE	E-CONTINUE ON ANOTHER PAGE IF	:
Concurrence of	CDRH, Office of	Device Evaluation (ODE)	
			¥*
·	•		
rescription Use <u>V</u> Per 21 CFR 801.109)	OR	Over-The-Counter Use	
rec 27 Crit 601, 1031	2	(Optional Format 1-2-9	6)
	(Division Sign-Off) Division of Reproduct		
	and Radiological Devi	ces 9924 <b>4</b> 7	